Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $416.96, moving -1.72% from the previous trading session.

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...

It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...